Page 51 - Human Use News Today

Shares of PTC Therapeutics, Inc. (PTCT) are declining more than 34 percent on Friday morning trade after the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency has given a negative opinion to its conditional authorization and full marketing authorization of Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy.

Lebrikizumab is a monoclonal antibody that binds to cytokine IL-13, which has been implicated in driving the type-2 inflammatory loop in the skin, leading to skin barrier dysfunction.

These are the stocks posting the largest moves in midday trading.

(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyos (DSKYF.PK) Enhertu has been recommended for approval in the European Union by the C...

EMA Committee for Medicinal Products for Human Use Adopts Positive ...

- Final European Commission decision expected within 67 days after positive opinion; if approved, first European Union launch planned in Germany in early 2024 COPENHAGEN, Denmark, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion and recommended the approval of TransCon PTH (palopegteriparatide) as a parathyroid hormone (PTH) replace...

Moderna, Inc. (NASDAQ: MRNA) shares are trading higher after the EMA Committee for Medicinal Products for Human Use adopted an opinion recommending authorization of the company's updated COVID-19

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion regarding a Type II variation application to extend the therapeutic indication of melphalan flufenamide for use in adult patients with multiple myeloma who have received at least 2 prior lines of treatment and whose disease is refractory to lenalidomide and the last line of therapy.

NGS assay demonstrated a broader detection range than standard in vivo tests with comparable or higher analytical sensitivity ...

As legislation to overhaul the practices of pharmacy benefit managers snakes its way through Congress, the PBM industry faces an uphill battle.